Released Nov 7, 2019, after the close
10-Q filed Nov 8, 2019, 39 days after period end · 0001564590-19-041909
Q3 2019 · 10-Q
Revenue$12.28M$12.28M +56.7% vs Q3 2018+16.6% vs Q2 2019
Net Income-$12.91M-$12.91M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.56-$0.56 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$12,735,000N/M
Operating Cash Flowderived-$16,121,000N/M
Free Cash Flowderived-$16,788,000N/M
Margins · derived
Operating margin-103.7%+25.9 pt vs Q3 2018
Net margin-105.2%+25.5 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|
| Revenue | $12.28M | $7.84M | $17.50M |
| Net Income | -$12.91M | -$10.24M | -$1.42M |
| EPS Diluted | -$0.56 | -$21.26 | -$3.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR